Resources

Proteomics Databases



Metabolomics Databases

• • Monoclonal Antibody Disulfide Bond Characterization and Integrity Analysis

  Monoclonal antibodies (mAbs) are a cornerstone of modern biopharmaceutical development and therapeutic applications. Their structural integrity directly determines drug stability, safety, and biological activity. Disulfide bonds, as critical stabilizing elements of antibody higher-order structure, maintain the three-dimensional conformation and functional properties of antibodies. Accurate characterization of disulfide bond connectivity and integrity is essential for antibody development, manufacturin......

• • Single-Cell iTRAQ Proteomics

  In life science research, understanding the diversity and complexity of cellular functions is fundamental. However, most proteomics studies are conducted on bulk cell populations. Although such approaches provide averaged protein expression profiles, they obscure heterogeneity among individual cells. In recent years, the development of single-cell iTRAQ proteomics has provided a powerful strategy for resolving cellular heterogeneity, enabling the investigation of fine-scale regulatory mechanisms at th......

• • Antibody Diversity And Specificity Analysis vs ELISA: Method Selection and Research Use Cases

  Technical guide for Antibody Diversity And Specificity Analysis vs ELISA: Method Selection and Research Use Cases.

• • Antibody Diversity And Specificity Analysis Troubleshooting: Causes, Checks, and Fixes for Research Workflows

  Technical guide for antibody diversity and specificity analysis troubleshooting with workflow checks, de novo sequencing decision logic, and interpretation limits.

• • How to Plan an Antibody Protein Sequencing Project When the Antibody Gene Sequence Is Unknown

  Antibody protein sequencing is often requested when a functional monoclonal antibody exists, but the antibody gene sequence is unknown, missing, or no longer trusted. A legacy hybridoma may still produce IgG, a recombinant batch may bind as expected, and internal records may list clone names or assay data, yet the exact VH and VL sequences needed for expression design, rescue, or documentation were never archived.

• • Epitope vs Antigen: Method Selection and Research Use Cases

  Decision-focused technical guide for selecting between antigen identification, epitope mapping, and staged de novo sequencing workflows in antibody-reactive samples.

• • How to Improve Antibody Diversity And Specificity Analysis Optimization in Research Workflows

  A decision-focused guide for immunology and antibody teams on resolving ambiguous diversity and specificity conclusions with protein-level sequence interpretation and validation planning.

• • Antigen vs Epitope: Method Selection and Research Use Cases

  Method-selection guide comparing antigen-level identification, epitope mapping, and de novo sequencing pathways for sequence-uncertain research projects.

• • How Much Does Hybridoma Sequencing Cost? Key Factors in Antibody Gene Recovery

  Researchers evaluating hybridoma sequencing often ask for a single price before hybridoma status, reporting scope, and deliverable needs are clear. That question is understandable. Grant budgets, vendor comparisons, and rescue timelines all depend on cost predictability. However, hybridoma sequencing is rarely a one-size-fits-all service.

• • Hybridoma Sequencing vs Antibody Protein Sequencing: Which Method Is More Suitable?

  Antibody sequence recovery projects often reach a fork in the road. A team may have a functional monoclonal antibody, but the available material may be hybridoma cells, RNA, purified IgG, or only a partial historical record. Hybridoma sequencing recovers VH and VL from hybridoma- derived nucleic acids. Antibody protein sequencing recovers sequence information from purified antibody protein, usually through LC-MS/MS and peptide assembly.